Endoglin negatively regulates transforming growth factor β1-induced profibrotic responses in intestinal fibroblasts

British Journal of Surgery

Volumn 97, Issue 6, 2010, Pages 892-901

  Burke, J P ^a   Watson, R W G ^a   Mulsow, J J ^a   Docherty, N G ^a   Coffey, J C ^a   O'Connell, P R ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CELL CULTURE; CONFOCAL MICROSCOPY; CROHN DISEASE; FIBROBLAST; HUMAN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BLOTTING, WESTERN; CELLS, CULTURED; CROHN DISEASE; FIBROBLASTS; HUMANS; MICROSCOPY, CONFOCAL; MIDDLE AGED; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77952777431     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6996     Document Type: Article

References (47)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures, Inflamm Bowel Dis 2004; 10: 55-60.
3. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988; 94: 257-265.
4. Burke JP, MulsowJJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102: 439-448.
5. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR. Expression and regulation of connective tissue growth, factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2006; 93: 1290-1296.
6. Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2004; 91: 72-77.
7. MulsowJJ, Watson RW, FitzpatrickJM, O'Connell PR. Transforming growth, factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ER.K1/2 mitogen activated protein kinase cell, signaling. Ann Surg 2005; 242: 880-887.
8. Regan MC, Flavin BM, Fitzpatrick JM, O'Connell PR. Stricture formation in Crohn's disease: the role of intestinal fibroblasts. Ann Surg 2000; 231: 46-50.
9. di Mola FF, Friess H, Scheuren A, Di Sebastiano P, Graber H, Egger B et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999; 229: 67-75.
10. Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G et al. Transcriptomic analysis of intestinal, fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm. Bowel Dis 2008; 14:1197-1204.
11. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C172-C182.
12. Fonsatti E, Altomonte M, Arslan P, Maio M. Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets 2003; 4: 291-296.
13. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends CardiovascMed 2008; 18: 25-32.
14. Bernabeu C, Conley BA, Vary CP. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007; 102: 1375-1388.
15. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002; 46: 1857-1865.
16. Prieto M, Ródriguez-Peña AB, Düwel A, Rivas JV, Docherty N, Pérez-Barriocanal F et al. Temporal changes in renal endoglin and TGF-beta 1 expression following ureteral obstruction in rats. J Physiol Biochem 2005; 61: 457-467.
17. Sadlier DM, Connolly SB, Kieran NE, Roxburgh S, Brazil DP, Kairaitis L et al. Sequential extracellular matrix-focused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrosis in murine Adriamycin-induced nephropathy. J Biol Chem 2004; 279: 29670-29680.
18. Clemente M, Nunez O, Lorente R, Rincón D, Matula A, Salcedo M et al. Increased intrahepatic and circulating levels of endoglin, a TGF-beta 1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 2006; 13: 625-632.
19. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998;273: 21145-21152.
20. Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, O'Connell PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor betal -mediated activation of intestinal fibroblasts. Br J Surg 2009;96:541-551.
21. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB et al. IGF-I and procollagen alpha 1(1) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am. J Physiol Gastrointest Liver Physiol 2000; 279: G1307-G1322.
22. Beddy DJ, Watson WR, FitzpatrickJM, O'Connell PR. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease, J Am Coll Surg 2004; 199: 234-242.
23. Docherty NG, O'Sullivan OE, Healy DA, Murphy M, O'Neill AJ, Fitzpatrick JM et al. TGF-betal-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am. J Physiol Renal Physiol 2006; 290: F1202-F1212.
24. Liu X, Wen FQ, Kobayashi T, Abe S, Fang Q, Piek E et al. Smad3 mediates the TGF-beta-induced contraction of type I collagen gels by mouse embryo fibroblasts. Cell Motil Cytoskeleton 2003; 54: 248-253.
25. Sumiyoshi K, Nakao A, Setoguchi Y, Okumura K, Tsuboi R, Ogawa H. Smads regulate collagen gel contraction by human dermal fibroblasts. Br J Dermatol 2003; 149: 464-470.
26. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925-1933.
27. Cheifetz S, Bellón T, Calés C., Vera S, Bernabeu C., Massagué J et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-19030.
28. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608.
29. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD 105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61: 7846-7854.
30. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res 2006; 69: 845-854.
31. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325-334.
32. Roberts AB, Russo A, Felici A, Flanders KC. Smad3 : a key player in pathogenetic mechanisms dependent on TGF-beta. Ann NY Acad Sci 2003; 995: 1-10.
33. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005; 204: 574-584.
34. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007; 210: 456-468.
35. Schemer O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-betal and BMP-7 signaling. J Biol Chem. 2007; 282: 13 934-13 943.
36. Pérez-Gómez E, Villa-Morales M, Santos J, Fernández-Piqueras J, Gamallo C, Dotor J et al. A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res 2007; 67: 10268-10277.
37. Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smadl pathway. Oncogene 2007; 26: 7240-7250.
38. Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P et al. CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res 2004; 24: 1337-1345.
39. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CP, Bernabeu C. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem. 2004; 279:32 858-32 868.
40. Shi Y, Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998; 94: 585-594.
41. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem 1999; 274: 703-709.
42. Latella G, Vetuschi A, Sferra R, Catitti V, D'Angelo A, Zanninelli G et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamineinduced hepatic fibrosis in mice. Liver Int. 2009; 29: 997-1009.
43. Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, Catitti V et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest. 2009; 39: 145-156.
44. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbetal responses in human proximal-tubule epithelial cells. Biochem. J 2006; 393: 601-607.
45. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes - but without modulating bone morphogenetic protein 7 signaling. Hepatology 2009; 49: 2021-2030.
46. Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46: 1257-1270.
47. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.